Shalby Ltd (SHALBY) Q4FY26 Concall Summary - Mar-2026 Qtr
Performance Overview
- The company reported healthy improvement across key financial parameters, with a significant turnaround in profitability compared to the previous year, largely driven by a change in the tax regime.
- The hospital business demonstrated resilience, with growth in standalone revenue and operational metrics like ARPOB, despite challenges from geopolitical situations impacting international patient flow.
- The Shalby Medtech (implant) division achieved a significant milestone by reporting its second consecutive quarter of positive EBITDA, transitioning from an investment phase to a growth and execution phase.
- The company has been making strategic investments in high-growth specialties like oncology and robotics, which are expected to drive future revenue and profitability from Q2 FY27 onwards.
- Management addressed operational challenges, including doctor attrition and underperformance in certain units, stating that these issues have been stabilized in Q4 and a strong recovery is anticipated.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.